Breaking News, Financial News

Financial Reports: Alexion

Soliris sales up 44% for the year

Alexion
 
4Q Revenues: $599.5 million (+36%)

4Q Earnings: $153.3 million (loss of $19.0 million 4Q13)

FY Revenues: $2.2 billion (+44%)

FY Earnings: $656.9 million (earnings were $252.9 million FY13)

Comments: Soliris sales were $599 million in the quarter, up 36% and to $2.2 billion for the year, up 44%. R&D expenses were up 50% to $129.1 million in the quarter and up 62% to $513.8 million for the year.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters